A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 12 Jan 2012
At a glance
- Drugs Bendamustine; Bortezomib; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms VERTICAL
- Sponsors Millennium
- 12 Jan 2012 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
- 19 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Feb 2010 Planned end date changed from 1 Nov 2010 to 1 May 2010 as reported by ClinicalTrials.gov.